Herpes simplex virus type 1 (HSV-1) is a neurotropic virus that causes a variety of clinically significant diseases ranging from superficial cutaneous lesions to life-threatening encephalitis (49) . The designation of HSV-1 as a neurotropic virus is based on its ability to produce both lytic and latent infections of neurons of the peripheral and central nervous systems. The extent to which a given strain of HSV-1 can gain access to and travel within neurons (neuroinvasiveness) and the relative efficiency with which a strain produces neuronal damage and death (neurovirulence) are major determinants of the diseaseproducing capabilities of that strain. Identification of the viral genes that control neuroinvasiveness and neurovirulence and elucidation of the functions of the protein products of these genes are necessary to understand the mechanism by which HSV-1 causes disease.
By definition, any viral gene which, when mutated, results in the failure of the virus to enter or spread in neurons or to replicate in epithelial or neuronal cells can be said to affect neuroinvasiveness or neurovirulence, respectively. Some viral genes, however, have unique properties which appear to function exclusively or predominantly in neurons. Notably, a number of viral genes which affect neurovirulence and which, collectively, determine whether infection will be productive or latent are located within the abbЈaЈcЈca repeat regions flanking the unique long and short regions of the HSV-1 genome ( Fig.  1 ) (reviewed in reference 50) .
The genes specifying the L/S junction-spanning transcripts (L/STs) and the ␥ 1 34.5 gene, are located within these repeat regions and constitute the subject of this paper. The L/STs are a series of 5Ј-coterminal polyadenylated RNAs transcribed from the same DNA strand as the latency-associated transcripts (LATs) (Fig. 1) (50) . The L/STs range in size from 2.3 to Ͼ9.0 kb and are expressed at detectable levels only by mutant viruses that express no functional ICP4 or that lack an intact ICP4 binding site at the transcription initiation site of the L/ST gene (50) . These properties suggest that ICP4 bound to its cognate binding site in the L/ST promoter blocks the expression of the L/STs. The L/STs overlap the 3Ј terminal 2.3 kb of the 8-kb minor LAT on the same strand, and, critical to the subject of this paper, the L/STs overlap and are antisense to the ␥ 1 34.5 gene (Fig. 1) .
The first and largest open reading frame (ORF) in the L/STs is ORF-P, which specifies the ORF-P protein (OPP) (Fig. 1C and Fig. 10 ). ORF-P is conserved in all HSV-1 strains whose genomes have been sequenced in this region. OPP is expressed at detectable levels only under conditions which allow expression of the L/STs (26, 50) . Overlapping the 5Ј half of ORF-P, and encoded by the same DNA strand but in another reading frame, is ORF-O, which encodes the ORF-O protein (OOP) (Fig. 1C) . In strain 17synϩ, ORF-O is approximately 300 codons in length. In strains KOS, F, MGH10, and CVG2, a single-base-pair substitution terminates ORF-O after approximately 160 codons. Randall et al. have recently provided evidence suggesting that, like ORF-P, ORF-O is downregulated by ICP4 (34) . The translational start codon of ORF-O lies immediately downstream of the TATA box in the L/ST promoter; thus, ORF-O is probably encoded by the LATs rather than the L/STs. Recently, however, Randall et al. have suggested that in strain F, ORF-O and ORF-P initiate from the same methionine codon and that the initiation of ORF-O at this codon results from frameshift or editing of its RNA (34) .
The L/STs overlap and are antisense to the ␥ 1 34.5 gene. The ␥ 1 34.5 gene is located between the genes specifying two major immediate-early (IE) transcriptional regulatory proteins, ICP0 and ICP4 (Fig. 1) . The ϳ8-kb LAT, specified by the opposite strand, overlaps and is antisense to the entire ICP0 and ␥ 1 34.5 genes. The ␥ 1 34.5 gene encodes ICP34.5, a protein with an apparent molecular mass of 44 kDa (2, 11, 15) . The ␥ 1 34.5 ORF (ORF-34.5) is conserved in all HSV-1 strains that have been sequenced to date (14, 18) . Viruses with deletions in ORF-34.5 are replication competent in vitro; however, they are highly attenuated for neurovirulence in vivo following intracranial inoculation of mice (6, 14, 35, (46) (47) (48) . Other properties of ␥ 1 34.5 mutant viruses include (i) more efficient replication at some primary sites of infection (e.g., the footpad and vagina) than at others (e.g., the eye) (49) , (ii) defective replication in the sensory ganglia of mice, guinea pigs, and rabbits and in the central nervous system of mice (6, 14, 30-32, 35, 45, 48) ; (iii) wild-type growth in most cell types but restricted growth in SK-N-SH (human neuroblastoma) (13) , CV-1 (African green monkey kidney) (32) , murine 10T1/2 (stationary-phase primary mouse embryo), and 3T6 cells (6, 7) ; (iv) premature shutoff of all protein synthesis (cellular and viral) following infection of SK-N-SH cells (12, 13) ; and (v) reduced establishment of latency compared to wild-type virus (31, 45) .
During the course of the studies of ICP34.5 just described, a number of mutant viruses were constructed and characterized. By virtue of the complete overlap of the ␥ 1 34.5 gene with the L/ST and the 8-kb LATs, mutations introduced into the ␥ 1 34.5 gene were also introduced into sequences specifying the L/STs and the LATs. Consequently, "␥ 1 34.5 mutant viruses" are either ORF-34.5 ORF-P double mutants or ORF-34.5 ORF-P ORF-O triple mutants (Fig. 1) .
Because ORF-O is probably contained in the LATs rather than the L/STs, as noted above, we focused the present investigation on the contribution of ORF-P to the phenotype of ORF-34.5 ORF-P double-mutant viruses. We approached this problem by using two genetic strategies. In the first, we mutated ORF-P without altering ORF-34.5, and in the second, we altered the transcriptional regulation of the L/STs by greatly increasing the levels of L/ST and ORF-P expression. We report here the construction and characterization of two mutant viruses: one, L/ST-n38, containing a nonsense mutation that terminates ORF-P translation at amino acid 38 but does not alter the sequence of ICP34.5 encoded by the complementary DNA strand ( Fig. 1G ; also see Fig. 10 ), and another, L/ST-4BS, containing a mutation in the L/ST promoter that derepresses L/ST expression by abrogating ICP4 binding to its cognate binding site near the transcription initiation site of the L/STs ( Fig. 1G ; also see Fig. 10 ). The properties of L/ST-n38 demonstrate that expression of a truncated OPP produces no observable phenotype relative to wild-type virus in vitro or in vivo. By contrast, L/ST-4BS, which is mutated in the ICP4 binding site in the L/ST promoter and overexpresses the L/STs and OPP, is highly attenuated following intracranial inoculation of juvenile mice, yet replicates efficiently in the mouse eye and trigeminal ganglia (TGG) without eliciting an adverse host response. Of special interest was the observation that L/ST-4BS induced cell-type-specific expression of both ␥ 1 34.5 transcripts and LATs since both types of transcript were abundant in Vero cells but barely detectable in mouse neuroblastoma cells (NB41A3). The significance of these findings to the assignment of specific functions to OPP and ICP34.5 can be summarized as follows: (i) ICP34.5 and not ORF-P is the neurovirulence factor responsible for attenuation of ORF-P ORF-34.5 double mutants and (ii) a factor or element affected by the 4BS mutation mediates cell-type-specific expression of the ␥ 1 34.5 gene and the LATs. TR L , U L , and IR L , terminal repeat, unique, and internal repeat sequences, respectively, of the long segment; IR S , U S , and TR S , internal repeat, unique, and terminal repeat sequences, respectively, of the short segment; bЈ, internal inverted repeat sequence bracketing U L ; cЈ, internal inverted repeat sequence bracketing U S ; aЈ, inverted sequence located between the bЈ and cЈ sequences and, in reverse orientation, at the genomic termini. (B) Expanded map of the internal repeat sequence bЈ-aЈ-cЈ lying between kbp 117 and 134 on the HSV-1 genome.
Plasmids. For subcloning purposes, pBamK (Fig. 1F) , containing the KOS BamHI K fragment from pSG28 (40) , and pNco (Fig. 1G) , containing the 1.75-kbp NcoI subclone of pBamK, were constructed as described previously (50) . Plasmid pL/ST-n38 (Fig. 1G ) is identical to pNco, except that it contains a single-base-pair transition in ORF-P. Mutagenesis was accomplished by in vitro phagemid mutagenesis with pNco as the parental plasmid and the mutant oligonucleotide 5Ј-ACCAGGTGACGCACCCGG-3Ј. The transition mutation from G to A (underlined) eliminates the cleavage site for the restriction enzyme PflMI. Plasmid pL/ST-4BS m (Fig. 1G ) is identical to pNco except for four singlebase-pair changes in the ICP4 binding site near the transcriptional start site of the L/STs. The mutations were introduced by in vitro phagemid mutagenesis with pNco as the parental plasmid and the mutant oligonucleotide 5Ј-GCGGCTCC TGCCAGCGCTCCTCCGGAGAGC-3Ј. The mutation of ATCGTCTCT to AG CGCTCCT generates a new restriction site for the endonuclease Eco47III.
For in vitro transcription and translation of L/ST ORF-P, a 2.6-kb SacI-NcoI fragment derived from pBamK was cloned into pGEM5Zf(ϩ) (Promega Corp., Madison, Wis.) to generate plasmid pL/ST-Nxi (Fig. 1H) . To construct pL/STNxiLM3 (Fig. 1H) , the 0.7-kb SacI-BstEII fragment of pL/ST-Nxi was replaced by the corresponding fragment from pL/ST-n38. Plasmid pL/ST-NxiLM3 was used to test the efficacy of the stop codon.
The plasmids used in transient-expression assays were as follows. Plasmid pWR-CAT, an expression vector carrying a promoterless chloramphenicol acetyltransferase (CAT) gene, was described previously (33) . A modified vector, pWR-CAT ϩ (Fig. 1I) , was used as the parent plasmid for all transient-expression plasmids constructed in this study. Plasmid pWR-CAT ϩ was constructed by cloning the EcoRI (blunt ended with Klenow)-HindIII linker from pGEM3ZF(ϩ) into the Ecl136II-HindIII sites of pWR-CAT. Plasmid pL/ST-U-CAT (Fig. 1I) , containing the L/ST promoter region, was constructed by cloning a fragment spanning the NcoI site at Ϫ935 through the entire 5Ј untranslated region of the L/STs to position ϩ122 in pWR-CAT ϩ . In pL/ST-4BS m -CAT (Fig. 1I) , the L/ST promoter (Ϫ935 to ϩ1) in pL/ST-U-CAT was replaced by the corresponding fragment (NcoI-BspEI) from pL/ST-4BS m , producing a plasmid in which the reporter CAT gene is driven by the L/ST promoter carrying the mutated ICP4 binding site. Effector plasmids, pSH, containing the wild-type ICP0 gene, and pn11, containing the wild-type ICP4 gene, have been described previously (9, 16) .
To generate L/ST mutant viruses, the following plasmids were constructed. p0V (Fig. J) contains the 7.1-kb PstI-DraI fragment from pSG28 cloned into the PstI-Ecl136II sites in pGEM3Zf(ϩ) (Promega). p0V-n38 contains the 0.7-kb Tsp509I-DraIII fragment from pLST-n38 cloned into the EcoRI-PflMI sites of p0V. p0V-4BS contains the 0.3-kb MscI-PflMI fragment from pLST-4BS m cloned into the same sites in p0V. p0V-4/38 contains the 0.7-kb Tsp509I-DraIII fragment from pLST-n38 cloned into the EcoRI-PflMI sites of p0V-4BS.
Riboprobes EBN9-LAT, EBNc3-LAT(S), 4Sma, and BbSLAT have been described previously (Fig. 1D) (50) . EBN9-LAT and EBNc3-LAT(S) were used to detect the L/STs; 4Sma was used to detect the ICP4 transcript; BbSLAT was used to detect the LATs. Riboprobe EBSN34.5, used to detect ICP34.5 transcripts, was derived from plasmid pEBSN34.5 ( Fig. 1E) containing the SacI-NotI fragment of pNco (50) .
Plasmids pEBNc3-LAT(S), pEBSN34.5, and pEBD1Ms ( Fig. 1E) were also nick translated and used as probes in Southern blot analysis. pNco, pEBNc3-LAT(S), and pEBSN34.5 were described above. pEBD1Ms contains the 1.3-kb DraI-MscI fragment spanning the a sequences cloned into the HincII site of pGEM3Zf(ϩ).
To express and purify OPP for the production of anti-OPP antibodies, a number of plasmids specifying glutathione S-transferase (GST) fusion proteins were constructed. In plasmid pG-L/ST (Fig. 1K) , the ORF-P sequence, from its translational start site through the DraI restriction site in the a sequences, was cloned in frame to the 3Ј end of the GST ORF in pGEX-2TK (Pharmacia Biotech Inc., Piscataway, N.J.) with BamHI linkers. To generate pG-L/ST-C (Fig.  1K) , the plasmid expressing only the carboxyl-terminal 52 amino acids of ORF-P, a 278-bp NotI-EcoRI fragment from pG-L/ST, was blunt ended with Klenow enzyme and cloned in frame with GST in pGEX-2TK.
Plasmid mutagenesis. Competent Escherichia coli CJ236 (dut ung) was transformed with plasmid pNco, and single-stranded phagemid DNA was prepared as instructed by the manufacturer (Promega). Oligonucleotide-directed mutagenesis was then performed by the Kunkel method (23) . The mutations were confirmed by the absence (pL/ST-n38) or appearance (pL/ST-4BS m ) of specific restriction enzyme sites and by DNA sequencing.
In vitro transcription and translation. Linearized template DNA (2 g) was transcribed in vitro with SP6 polymerase to generate capped RNA as specified by the manufacturer (Promega). Half of the RNA was used for in vitro translation; the other half was used for Northern blot analysis. In vitro translation was performed, as specified by the manufacturer (Promega), with rabbit reticulocyte lysate and either [ 35 S]cysteine or [ 35 S]methionine (New England Nuclear, Boston, Mass.). Aliquots (2.5 l) of in vitro-translated proteins were analyzed by denaturing polyacrylamide gel electrophoresis.
Gel mobility shift assays. To generate probes for use in-gel mobility shift assays and competition experiments, single-stranded 30-mer oligonucleotides corresponding to the plus and minus strands of the wild-type and mutated ICP4 binding sites were synthesized by the Molecular Biology Core Facility at the Dana-Farber Cancer Institute. The nucleotide sequence of the wild-type binding site is 5Ј-GCGGCTCCTGCCATCGTCTCTCCGGAGAGC-3Ј, and that of the mutated binding site is 5Ј-GCGGCTCCTGCCAGCGCTCCTCCGGAGAGC-3Ј. (The core ICP4 binding site is underlined.) Complementary single-stranded probes were annealed by heating to 98°C for 5 s followed by slow cooling to 68°C, incubation at 68°C for 1 h, and slow cooling to room temperature. Doublestranded probes were separated from unannealed single-stranded oligonucleotides by polyacrylamide gel electrophoresis (PAGE), cut out of the gel, and electroeluted overnight at 35 V. Gel-purified double-stranded probes were radiolabeled with T4 polynucleotide kinase (New England Biolabs, Beverley, Mass.) and [␥-
32 P]ATP (New England Nuclear). As the source of proteins, Vero cells were mock infected or infected with KOS or n12, an ICP4 null mutant (17) , at a multiplicity of infection of 10 PFU/cell. Extracts were prepared at 8 h postinfection (p.i.) by the method of Andrews and Faller (3) . Individual binding-reaction mixtures contained 6 to 7 g of protein extract, 1 ng of 32 P-labeled probe, 20 mM HEPES, 50 mM NaCl, 1 mM EDTA, 10% glycerol, and 4 g of poly(dI-dC) (Boehringer Mannheim, Indianapolis, Ind.). The binding-reaction mixtures were incubated for 30 min at 25°C. For antibody supershift assays, 1 l of 58S (a monoclonal antibody to ICP4 [43] ) was added after the 30-min binding reaction and the mixture was incubated for an additional 10 min at 25°C. Protein-DNA complexes were separated by electrophoresis in 4% polyacrylamide gels (80:1 acrylamide/bisacrylamide) prepared and run in 0.5 ϫ Tris-borate-EDTA buffer (TBE) (39) . The gels were prerun at 170 V for 1 h. In competition experiments, radiolabeled probe and unlabeled competitor probe were premixed before the addition of buffer and extract. The gels were dried on filter paper and exposed to XAR-5 film (Kodak, Rochester, N.Y.).
Transient-expression assays. Vero cells (10 6 cells) were plated in 60-mmdiameter petri dishes 24 h prior to transfection. The medium was replaced 3 h prior to transfection. Reporter and effector plasmids were transfected by the calcium phosphate-bis-ethane sulfonic acid method described by Ausubel et al. (4) . Cell lysates for determination of CAT activity were prepared approximately 40 h posttransfection and assayed by the phase extraction method (42) as modified by Frazier et al. (20) . For transfection/superinfection assays, monolayers were infected with virus at an MOI of 10 PFU/cell 24 h after transfection and lysates were prepared at 3, 6, 12, and 24 h p.i.
Isolation of mutant and rescuant viruses. To isolate mutant viruses, L/ST-n38 and L/ST-4BS, Vero cells (5 ϫ 10 5 cells) were seeded in 60-mm-diameter dishes and cotransfected 24 h later with 1 g of infectious 7134 DNA and 10 g of a DNA fragment containing the mutation (i.e., the 7,002-bp PstI-EcoRV fragment from p0V-n38 or the 7,129-bp PstI-EcoRI fragment from p0V-4BS [ Fig. 1J] ). Six days later, when cytopathic effects were generalized, the cultures were harvested, frozen and thawed, sonicated for 1 min, clarified by low-speed centrifugation, plated on Vero cell monolayers, and overlaid with methylcellulose. After incubation at 37°C for 4 days, 2 ml of 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal) (300 g/ml) in neutral red was added to each 35-mm petri dish. Parental 7134 virus would yield blue plaques because the ICP0 sequence has been replaced by lacZ. Recombinant plaques would be white if the wild-type ICP0 sequences had replaced lacZ sequences. In this way, the n38 and 4BS mutations were "piggybacked" simultaneously into the genome in a subset of recombinants. White plaques were picked and assayed by Southern blot analysis for the presence of the desired mutation in both copies of the b repeat sequences. Mutants were subjected to two additional rounds of plaque purification. One viral isolate obtained from cotransfection of infectious 7134 and linearized p0V-n38 DNAs was designated L/ST-n38, whereas an isolate from the cotransfection of 7134 and p0V-4BS DNAs was designated L/ST-4BS.
To isolate rescuant viruses, L/ST-n38R and L/ST-4BSR, cotransfections were performed as described above with 1 g of infectious L/ST-n38 or L/ST-4BS DNA and 0.5 g of the wild-type 1.75-kB NcoI fragment from p0V. Rescuants generated from cotransfections were identified by Southern blot analysis, plaque purified two additional times, and designated L/ST-n38R and L/ST-4BSR, respectively.
Southern blot analysis was used to confirm the genotype of L/ST-n38, 4ST-4BS, and rescuants thereof. For this purpose, 5 ϫ 10 5 Vero cells were infected with 0.01 PFU of the designated viruses per cell. When cytopathic effects were generalized, the cells were scraped into medium, frozen at Ϫ70°C, thawed, sonicated for 1 min, pelleted, and resuspended in 400 l of lysis buffer (10 mM Tris-HCl [pH 8], 10 mM EDTA [pH 8], 2% sodium dodecyl sulfate [SDS] , 400 g of proteinase K per ml.). Lysis was carried out overnight at 37°C. DNA was extracted once with phenol and twice with phenol-chloroform-isoamyl alcohol (25:24:1), ethanol precipitated, and resuspended in deionized, distilled H 2 O. One-third of the DNA yield was digested by restriction enzymes, separated in an 0.8% agarose gel, and transferred onto a nitrocellulose membrane by the method of Southern (39, 44) . The membranes were probed with nick-translated pEBSN34.5, pEBNc3-LAT(S), or pEBD1Ms. Briefly, the nick translation reaction mixture contained 0. Western blot analysis. Cells were infected at a multiplicity of 10 PFU/cell and harvested at the indicated times p.i. Lysates were prepared as follows. Infected monolayers were washed twice with cold phosphate-buffered saline (PBS) (39) , and scraped into PBS in the presence of protease inhibitors (10 g of TPCK [N-tosyl-L-phenylalanine chloromethyl ketone] per ml and 2 mM phenylmethylsulfonyl fluoride [PMSF] ). The cells were pelleted and resuspended in a small volume of PBS-TPCK-PMSF, aliquoted, and quick-frozen in liquid nitrogen. Aliquots were thawed only once for use. The protein concentration was determined with the Bio-Rad protein assay reagent, as specified by the manufacturer. Cell lysis was completed by the addition of SDS-PAGE loading buffer (50 mM Tris, 2% SDS, 0.7 M ␤-mercaptoethanol, 2.75% sucrose). Proteins were separated by denaturing polyacrylamide gel electrophoresis (10) and transferred to Immobilon-P membranes (Millipore Corp., Bedford, Mass.).
Western blot analysis was performed as follows. Blots were blocked for 2 h with 3% bovine serum albumin (BSA) in PBST (PBS containing 0.05% Tween 20). The primary antibody was diluted in 3% BSA-PBST and incubated with the blot for 1 h. The blot was then washed with two quick rinses, two 5-min washes, and three 10-min washes with PBST; it was then blocked again with 3% BSA-PBST for 20 min. The same procedure was repeated with the secondary antibody, rabbit anti-mouse immunoglobulin G (Cappel Laboratories, Durham, N.C.), when applicable, and with horseradish peroxidase-conjugated goat antirabbit immunoglobulin G (Bio-Rad). Immunodetection was performed with the ECL chemiluminescence reagent from Amersham Life Science (Arlington Heights, Ill.) and visualized with BioMax-MR film (Kodak).
Mouse monoclonal antibodies H1112 and H1113 are specific for ICP0 and ICP27, respectively (1) (Goodwin Institute for Cancer Research, Plantation, Fla.). Monoclonal antibody 58S, specific for ICP4, was generated from a hybridoma cell line obtained from the American Type Culture Collection (43) . Rabbit polyclonal antibody R45, which is directed against gD, was kindly provided by R. Courtney (Pennsylvania State University Health Science Center, Hershey, Pa.). Rabbit polyclonal antibody D111, directed against OPP, was generated in this laboratory as described below.
G-L/ST-C fusion protein purification. To prepare the G-L/ST-C fusion protein, an overnight culture of bacteria transformed with pG-L/ST-C was diluted 1:50 and allowed to grow until its optical density at 595 nm reached 1.0. Fusion protein expression was induced by the addition of isopropyl-␤-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. At 2 h after induction, bacteria were pelleted and resuspended in Tris-buffered saline (TBS) (39) containing 10 mM EDTA, 75 g of TPCK per ml, 2 mM PMSF, and 2 mM leupeptin. The bacteria were lysed by sonication, incubation with Triton X-100 (final concentration, 1%), and rocking for 30 min at 4°C. The lysate was cleared by centrifugation for 15 min at 26,890 ϫ g in an SS34 rotor. Glycerol was added to the supernatant fluid to a final concentration of 10%. The G-L/ST-C fusion protein was purified on glutathione-Sepharose 4B beads (Pharmacia) as specified by the manufacturer instructions and eluted from beads with 20 mM glutathione in 100 mM Tris [pH 8]-120 mM NaCl.
Preparation of antibodies to OPP. Rabbit polyclonal antibodies were raised against the purified G-L/ST-C fusion protein by HRP, Inc (Denver, Pa.). Two New Zealand White rabbits were inoculated intradermally with 250 g of G-L/ ST-C each and given booster doses three times at 2-week intervals by subcutaneous dorsal injections of 125 g of G-L/ST-C prior to obtaining antisera. Antisera from both rabbits reacted with G-L/ST-C in Western blot analysis. Anti-G-L/ST-C antibodies were purified from one of the antisera, DF111, by the blot purification method of Harlow and Lane (22) .
Analysis of infected-cell polypeptides. Vero cells (5 ϫ 10 5 cells) or SK-N-SH cells (1 ϫ 10 7 cells) were seeded in 35-mm-diameter petri dishes 24 h prior to infection. The cells were infected with the indicated viruses at a multiplicity of 10 PFU/cell. At the designated times p.i., the culture medium was replaced with 1 ml of methionine-minus medium (ICN Biomedicals, Inc., Costa Mesa, Calif.) supplemented with 50 Ci of [
35 S]methionine (New England Nuclear). Monolayers were labeled for 30 min at 37°C and then processed as described above to obtain protein lysates. Individual proteins in lysates (5 g of Vero and 10 g of SK-N-SH cell lysate) were separated by SDS-PAGE and analyzed by autoradiography as described previously (24) .
PAGE. SDS-PAGE of infected cell lysates was performed by the method of Laemmli (24) . Protein samples were boiled for 5 min in sample buffer (50 mM Tris, 2% SDS, 0.7 M ␤-mercaptoethanol, 2.75% sucrose, Coomassie blue). In vitro-translated proteins were also analyzed on Tricine gels. Northern blot analysis. Total-cell RNA was isolated and Northern blot analysis was performed as previously described (50) with two exceptions. First, for Northern blot analysis, 7.5 g of RNA was used per lane, and second, after overnight hybridization of the 32 P-labeled probe, the final wash in 0.1ϫ SSC-0.1% SDS was performed twice for approximately 50 min per wash. (0.1ϫ SSC is 15 mM NaCl plus 1.5 mM sodium citrate [pH 7].) Riboprobes were transcribed from the SP6 promoter in the vector as instructed by the manufacturer (Promega).
Animal procedures. For neurovirulence assays, 3-week-old female BALB/C mice (Charles River Breeding Laboratories, Inc., Kingston, N.Y.) were anesthetized with sodium pentobarbital and inoculated intracranially with 10-fold dilutions of virus stock (n ϭ 6 to 10 per dilution) in a volume of 30 l. The mice were monitored for 21 days, and the 50% lethal dose was calculated by the method of Reed and Muench (36) .
For tests of latency and reactivation, 7-week-old randomly bred CD-1 mice (Charles River Breeding Laboratories) were anesthetized with sodium pentobarbital, both corneas were scarified, and 10 6 PFU of virus in 10 l was added to each eye as described previously (28) . At the indicated times p.i., both eyes of four mice were swabbed with cotton swabs dampened in cell culture medium. The material on the swab was suspended in 1 ml of cell culture medium. Two mice were also sacrificed at each time point, and their TGG were excised and frozen. Ganglion homogenates were prepared by thawing and homogenizing with 10 strokes of a Kontes pellet pestle (Fisher Scientific, Pittsburgh, Pa.). Eye swab material and ganglion homogenates were assessed for infectious virus by standard plaque assays in Vero cell monolayers.
For reactivation assays, mice were sacrificed 30 days after infection. Each TGG was removed, cut into eight pieces, and explanted into one well of a 24-well dish containing 2 ϫ 10 5 Vero cells in suspension. On each day postexplant, for 15 or 21 days, 150 l of culture medium was removed and assayed for infectious virus. Fresh medium (150 l) was added back to the cocultivation to maintain the medium volume. To assay for infectious virus, 10 5 Vero cells were infected in suspension with the 150 l of the cocultivation medium; cytopathic effects were scored (ϩ or Ϫ) on day 5 after infection.
RESULTS
Sequence analysis of the 2.3-kb L/ST region. The DNA sequences used throughout these studies were derived from HSV-1 strain KOS. Since only the sequence of the L/ST promoter region of strain KOS had been published prior to these studies (5), we subcloned and sequenced the region corresponding to the 2.3-kb L/ST. Comparison of the KOS DNA sequence with that of HSV-1 strains 17synϩ, F, MGH-10, and CVG-2 revealed a nearly identical sequence, confirming that this region of the genome is highly conserved among various strains of HSV-1 (data not shown). The L/ST promoter region, as well as sequences containing the 5Ј end of the L/STs, are also highly homologous to the corresponding region in HSV-2 strain HG52 (26, 29) . As shown by the alignment of amino acid sequences, OPP of strain KOS is nearly identical to OPP of other HSV-1 strains (Fig. 2) . The only major strain-specific difference lies in the variable number of AGV repeats near the amino terminus of the protein. These repeats correspond to the previously reported ATP repeats in the carboxy terminus of ICP 34.5 (14, 18, 26, 29) .
The nonsense mutation (n38) terminates the translation of ORF-P at amino acid 38. To elucidate the functions of the L/STs and OPP, we introduced (i) nonsense mutations into both copies of ORF-P to yield a truncated protein consisting of only the amino terminus of OPP (the n38 mutation does not affect the amino acid sequence of ICP34.5 or the regulation of L/ST expression), and (ii) mutations into both copies of the ICP4 binding sites near the transcriptional start site of the L/STs that significantly enhance L/ST expression (and hence OPP expression) by eliminating ICP4-mediated repression.
To create the n38 nonsense mutation, we introduced a single G-to-A nucleotide transition in ORF-P, creating a termination codon at position 38 of this 225-codon ORF (Fig. 1M) . This mutation disrupts a PflMI restriction enzyme cleavage site, thereby facilitating the identification of the mutation in the plasmid and in mutant viral constructs. Unlike previously published mutations in this region of the genome, the n38 mutation is a single-phase nonsense mutation. Therefore, other proteins that may be encoded by this sequence on the same or opposite DNA strands would not be prematurely terminated. The n38 mutation does not alter ORF-34.5 coding specificity because the single-base-pair transition occurs at the wobble position of codon 180. The mutation does alter ORF-O, however, changing amino acid 93 from Arg to Thr.
Prior to introduction of the mutation into the viral genome, the effect of the substitution on OPP synthesis was examined by in vitro transcription-translation. In the uncoupled in vitro transcription-translation system, the lengths of the transcript and the translated protein are dictated by the location of the restriction enzyme cleavage site used to linearize the expression plasmid. pLST-Nxi and pLST-NxiLM3, containing wild-type and mutant ORF-P sequences, respectively, were linearized at the restriction sites shown in Fig. 3A . In vitro-transcribed RNAs generated from the linearized plasmids were divided into aliquots for use in Northern analysis and in vitro translation. As shown by the blot in Fig. 3B , which was probed with riboprobe EBN9-LAT for L/ST sense RNA (Fig. 1D) , linearization of the plasmid containing wild-type ORF-P at consecutive restriction sites downstream of the L/ST cap site resulted in the synthesis of progressively longer RNAs (Fig. 3B,  lanes 1 to 6) . As one would expect of a nonsense mutation that does not affect transcription, in vitro transcription from the mutant plasmid yielded RNAs (lanes 7 and 8) that were the same size as the corresponding wild-type RNAs (lanes 5 and 6). Because the polyadenylation site of the 2.3-kb L/ST lies between the DraI and MscI sites (Fig. 3A) , RNAs synthesized from the MscI-linearized plasmid (MscI-RNAs) represent the entire coding capacity of the 2.3-kb L/ST (Fig. 3B, lanes 6 and 8) .
An aliquot of each in vitro-transcribed RNA was used for in vitro translation (Fig. 3C) 6) . The molecular mass of this protein is similar to the theoretical molecular mass of OPP (23 kDa), suggesting that the observed protein band was derived from ORF-P. Unlike in vitro translation of wild-type RNA, translation of n38 RNA yielded no 26-kDa band, demonstrating that the n38 mutation terminated translation (Fig. 3C, lanes 7 and 8) . In this in vitro system, translation of n38 should have produced a short (37-amino-acid) peptide. To determine if this was the case, protein translated from n38 DraI-RNA and n38 MscI-RNA in the presence of [
35 S]Met was analyzed on a 20% denaturing Tricine polyacrylamide gel. A band corresponding to the 37-amino-acid peptide product of n38 RNA was detected in this test (data not shown). Because the RNAs containing the n38 mutation encode an otherwise full-length ORF-P, these results confirm that the single G-to-A transition terminated the translation of ORF-P.
The ICP4 binding-site mutation (4BS) abrogates ICP4 binding at the L/ST transcriptional start site and significantly enhances expression from the L/ST promoter. To disrupt ICP4-mediated repression of L/ST expression, we introduced four single-base-pair substitution mutations into the ICP4 binding site in the L/ST promoter (Fig. 1M) . These mutations created a new Eco47III restriction enzyme site, facilitating the identification of this mutation in plasmid and recombinant viral constructs. The effects of these mutations were first evaluated in vitro by gel mobility shift and transient-expression assays before they were introduced into the viral genome.
In gel mobility shift assays, proteins from infected-cell lysates formed a supershiftable complex with a labeled probe containing the wild-type ICP4 binding site but not with a probe containing the four single-base-pair substitution mutations (Fig.  4A ). This complex was supershifted by an ICP4-specific antibody. These findings were confirmed in a series of transientexpression and transfection/superinfection assays designed to determine the effect of the 4BS mutation on transcription from the L/ST promoter. In the first series of experiments, Vero cells were cotransfected with reporter constructs containing the L/ST promoter with the wild-type (pL/ST-U-CAT) or mutated (4BS; pL/ST-4BS m -CAT) ICP4 binding site and effector plasmids, pn11 and pSH, expressing ICP4 and ICP0, respectively. At 40 h posttransfection, the cells were harvested and processed for CAT activity. Whereas expression from the wildtype promoter was repressed in the presence of ICP4, expression from the promoter containing the 4BS mutation was strongly activated, demonstrating that ICP4 is able to activate the L/ST promoter but through a mechanism not involving the ICP4 consensus binding site in the L/ST promoter (Fig. 4B) . To ascertain whether the 4BS mutation specifically affected regulation by ICP4 and not all regulators of gene expression, we cotransfected the wild-type and 4BS reporter plasmids with the ICP0-expressing plasmid, pSH. The responses of the wildtype and 4BS constructs to ICP0 were essentially identical (Fig.  4C ) but were distinct from the responses of these plasmids to ICP4 (Fig. 4B) . Thus, as reported previously, expression from both plasmids was high following cotransfection with low levels of ICP0 whereas higher levels of ICP0 resulted in lower levels of CAT activity (5). These results suggest that the 4BS mutation does not deregulate the L/ST promoter indiscriminately and that the ICP4 binding site is not a target of ICP0 or ICP4 activation. Together with the findings from gel mobility shift assays, the results of transient-expression assays with a 4BS reporter construct indicate that ICP4 cannot bind to the mutated binding site to repress L/ST expression.
The cotransfection experiments examined the effects of specific viral regulatory proteins on the L/ST promoter containing the 4BS mutation. Because L/ST promoter activation following superinfection may better reflect promoter function during m -CAT (4BS MUT), containing the mutated ICP4 binding site. Reporter plasmids were cotransfected with increasing amounts of the ICP4-expressing plasmid, pn11 (16) (B) or the ICP0-expressing plasmid, pSH (9) (C). Cells were harvested at 40 h posttransfection or at the times indicated, and CAT enzyme activity was assayed. Data points represent the average activities in two separately transfected plates. Transfection of pWR-CAT ϩ , the promoter-less reporter plasmid, in the presence or absence of the effector plasmids, yielded background levels of CAT activity (data not shown). At 24 h after transfection of reporter plasmids alone, Vero cells were mock superinfected or superinfected with n12 or KOS at an MOI of 10 PFU/cell (D). The cells were harvested at 3, 6, 12, and 24 h p.i. A 9 h p.i., an additional data point was determined for 4BS reporter-transfected and KOS-superinfected Vero cells.
natural viral infection, we performed a transient-expression/ superinfection assay in which transfected Vero cells were mock infected or infected with KOS or n12 virus 24 h after transfection. At 3, 6, 12, and 24 h p.i., the cells were processed for CAT activity. As shown in Fig. 4D , expression from the wild-type promoter construct was repressed by superinfection with KOS (ICP4 ϩ ) but not n12 (ICP4 Ϫ ). Expression from the mutated 4BS construct was also high following superinfection with either KOS or n12, demonstrating that introduction of the 4BS mutation into the L/ST promoter derepressed expression in the context of wild-type viral superinfection. The mutated 4BS construct was more active following superinfection with KOS than with n12, consistent with the data presented in Fig. 4B and demonstrating that ICP4 and ICP0 (KOS) or only ICP0 (n12) can activate the mutated L/ST promoter in the context of viral infection (10) .
The introduction of the L/ST mutations n38 and 4BS into the viral genome was facilitated by the availability of 7134, an ICP0-null mutant virus in which both copies of the ICP0-coding region have been replaced by the E. coli lacZ coding sequence (9) . Thus, the L/ST mutations were "piggybacked" into both copies of the L/ST gene simultaneously with the rescue of both copies of ICP0, producing the white-plaque phenotype. The mutations in the resulting viruses (L/ST-n38 and L/ST-4BS) were also rescued by homologous recombination.
L/ST mutant viruses replicate efficiently in cells of neural and nonneural origin. ORF-34.5/ORF-P double mutants replicate to wild-type levels in permissive cells (e.g., Vero cells) but are growth restricted in certain neural cell lines (e.g., SK-N-SH cells) (12, 13) . To assess the ability of mutant viruses L/ST-n38 and L/ST-4BS to replicate in Vero and SK-N-SH cells, single-cycle growth experiments were performed with the wild-type virus, the two mutants, and the rescuant viruses. In Vero cells, L/ST-n38, L/ST-4BS, and the rescuants replicated as efficiently as wild-type virus, indicating that no spurious mutations in genes that affect replication efficiency were present in any of the viruses (Fig. 5A) . In SK-N-SH cells, however, L/ST-n38 replicated to wild-type levels whereas L/ST-4BS replicated to somewhat lower levels (Fig. 5B) . This experiment was repeated twice with identical results. The modest reduction in replication efficiency of L/ST-4BS in SK-N-SH cells was not observed with another ICP4 binding-site mutant virus, R7530 (25) .
To determine if the modest reduction in the growth of L/ST-4BS in SK-N-SH cells was specific for cells of neural origin, single-cycle growth experiments were also performed in undifferentiated and nerve growth factor-differentiated PC12 cells, mouse neuroblastoma cells (NB41A3), and dividing and resting HEL cells as a control nonneural cell type. No major differences were observed in the growth patterns of L/ST-4BS, L/ST-n38, or KOS in any of the cell lines tested (data not shown), suggesting that the modest reduction in replication efficiency of L/ST-4BS in SK-N-SH is specific for this cell type.
To further examine the general properties of the L/ST mutant viruses, patterns of protein synthesis in infected Vero cell extracts were analyzed at 3, 7, or 12 h p.i. by SDS-PAGE and by Western blot analysis with antibodies specific for ICP0, ICP4, ICP27, and glycoprotein D. Consistent with the similarities in the growth patterns of the L/ST mutants in Vero cells, the protein profiles of the mutants and their respective rescuants were indistinguishable from that of wild-type virus (data not shown).
Transcription of genes in the abbacca repeats in cells of nonneural and neural lineage by L/ST mutant viruses. L/ST expression by the mutant viruses, KOS, and the rescuant viruses was examined by Northern blot hybridization of total RNA harvested from infected Vero and NB41A3 cells (Fig.  6A) . The ICP4 nonsense mutant n12 was included as an L/STexpressing control (50) .
(i) L/STs. The L/STs were not detected in RNA from L/STn38-infected Vero or NB41A3 cells (Fig. 6A, lanes 4 and 11) ; this was expected since the L/ST promoter in L/ST-n38 contains a wild-type ICP4 binding site and is therefore subject to repression by ICP4. Similarly, the L/STs were not detected in KOS-infected (lanes 2 and 9) or L/ST-n38R-infected (lanes L/ST-4BS was due to the 4-bp substitution in the ICP4 binding site (lanes 7 and 14) .
(ii) ␥ 1 34.5 transcripts. Using a DNA probe specific for ␥ 1 34.5 transcripts, Chou and Roizman (15) Figure 6B also shows that the levels of ␥ 1 34.5-specific transcripts detected were uniformly greater in NB41A3 cells than in Vero cells and that the sizes of the transcripts detected in the two cell types differed in that the 5.2-kb transcript was evident in NB41A3 cells but not in Vero cells.
(iii) ICP0 and ICP4 transcripts. Northern blot analysis of total RNA harvested from infected Vero cells at 6 h p.i. demonstrated that ICP0 and ICP4 RNAs were expressed by both L/ST-n38 and L/ST-4BS at levels comparable to those of wildtype virus (Fig. 6C, lanes 2, 4, and 6 ). Because these transcripts were present at very low levels in NB41A3 cells at 6 h p.i., a considerably longer autoradiographic exposure was necessary to visualize the bands in lanes 8 to 14. As in Vero cells, levels of ICP0 and ICP4 transcripts were similar to those seen in KOS-infected cells. Although abundant ICP4 transcripts were present in n12-infected Vero cells, no functional ICP4 protein was made because of the nonsense mutation in the ICP4 gene; hence, ICP0 and ICP4 transcription is not repressed and these transcripts are made at higher-than-wild-type levels. Notably, overexpression of ICP0 and ICP4 transcripts by n12 relative to KOS was evident in Vero cells but not in NB41A3 cells (or PC12 cells [data not shown]). Thus, overexpression of these two transcripts is cell type specific.
(iv) LATs. Because the L/STs may function during HSV latency (50) , it was of interest to determine if the n38 or 4BS mutations have an effect on LAT expression in vitro. We therefore performed Northern blot analysis with a LAT-specific riboprobe, BbSLAT, with total RNA from Vero and NB41A3 cells harvested at 18 h p.i. with the L/ST mutant and rescuant viruses (Fig. 6D) . RNAs from KOS-infected cells (lanes 2 and 9) and n12-infected cells (lanes 3 and 10) were included as LAT-positive and LAT-negative controls, respectively.
In (Fig.  1D) . (B) ␥ 1 34.5 RNAs were detected with riboprobe EBSN34.5 (Fig. 1D) . (C) ICP0 and ICP4 RNAs were detected concurrently with riboprobes 0Hc-Xh and 4Sma (Fig. 1D) , respectively. The specificity of each riboprobe was determined independently (data not shown). ICP0 and ICP4 RNAs from NB41A3 cells (lanes 8 to 14) were detected after a twofold-longer autoradiographic exposure than RNAs from Vero cells (lanes 1 to 7) . The positions of ICP4 RNA and ICP0 are marked by black and white arrowheads, respectively. (D) LATs were detected with riboprobe BbSLAT (Fig. 1D) .
in NB41A3 cells relative to wild-type virus and L/ST-n38. Similar results were observed in PC12 cells. We conclude from these tests that LAT expression, like the expression of ␥ 1 34.5 transcripts, is cell type specific, being significantly higher in nonneural cells (Vero) than in cells of neural lineage (NB41A3 and PC12).
OPP expression by L/ST mutant viruses. Having demonstrated high-level expression of the L/STs by L/ST-4BS but not by L/ST-n38 in both Vero and NB41A3 cells, we attempted to assess the kinetics and levels of expression of OPP in Vero cells. To facilitate these studies, rabbit antibody (DF111) was raised against the C-terminal 52 amino acids of ORF-P fused to GST. Using this antibody, we first examined the ability of the L/ST mutant viruses and their respective rescuants to express OPP. Extracts of KOS-and n12-infected Vero cells were included as OPP-negative and -positive controls, respectively. As shown in Fig. 7 , OPP was not detected in Vero cells infected with KOS, L/ST-n38, and L/ST-4BSR, viruses that do not express the L/STs as demonstrated by Northern blot analysis (Fig. 6A) . In cells infected with L/ST-4BS, three proteins of approximately 24, 29, and 33 kDa were detected (Fig. 7, lanes  10 to 12) . The size of the 24-kDa band is consistent with the molecular mass of OPP (23 kDa) and with the size of the OPP band observed by in vitro transcription-translation (26 kDa) (Fig. 3) . The size and relative abundance of each protein species at 6, 12, and 18 h p.i. suggest that the 24-kDa protein is modified posttranslationally during the course of lytic infection. As anticipated, the 24-kDa protein was also detected in n12-infected Vero cells, although the appearance of the larger (29-kDa) species was delayed and these proteins were present in lower abundance relative to that in L/ST-4BS-infected cells. OPP expression by n12 and L/ST-4BS was also detected in NB41A3 cells, nerve growth factor-differentiated and undifferentiated PC12 cells, and SK-N-SH cells (data not shown), demonstrating that like expression of the L/STs, OPP expression is not cell type specific.
L/ST-4BS but not L/ST-n38 induces premature shutoff of protein synthesis in SK-N-SH cells. Gradual shutoff of host cell protein synthesis is observed after HSV infection of cultured cells (19) . In contrast to wild-type virus infection, ORF-34.5/ORF-P double-mutant viruses induce the shutoff of all protein synthesis (viral and host cell) at early times (3 to 6 h p.i.) in SK-N-SH cells relative to other cell types (13) . To examine protein shutoff in L/ST-n38-and L/ST-4BS-infected Vero and SK-N-SH cells, we performed metabolic labeling experiments. An ICP34.5-null mutant, 1771, derived from strain 17synϩ was included as a positive control, and wild-type strains KOS and 17synϩ were included as negative controls. In Vero cells, infection with the L/ST mutant viruses, both rescuants and the positive and negative control viruses, produced wild-type (KOS or 17synϩ) protein profiles, characterized by a gradual shift from host to viral protein synthesis over the 12-h period (Fig. 8A) . In SK-N-SH cells, L/ST-n38 and both rescuant viruses produced KOS wild-type-like protein profiles (Fig.  8B) . In contrast, L/ST-4BS and 1771 infection resulted in rapid and extensive shutoff of both viral and cellular protein synthesis relative to their respective wild-type viruses. Rescue of the 4BS mutation to produce the wild-type genotype (L/ST-4BSR) returned the protein synthesis profile to that seen with wildtype virus. The results obtained with L/ST-n38 suggest that the premature protein shutoff phenotype of the ORF-P ORF-34.5 double-mutant viruses in SK-N-SH cells is not likely to be a consequence of mutations in ORF-P but, rather, is a consequence of mutations in ORF-34.5. The molecular basis for the premature protein shutoff phenotype of L/ST-4BS is not clear and will be discussed below.
L/ST-4BS but not L/ST-n38 is attenuated for neurovirulence in mice.
Having shown that the protein shutoff phenotype is characteristic of L/ST-4BS but not L/ST-n38, we tested these mutants in vivo for their neurovirulence phenotypes and their ability to establish and reactivate from latency in mice.
To determine if the n38 and 4BS mutations result in the attenuated phenotype characteristic of ORF-P ORF-34.5 double-mutant viruses, we assessed the neurovirulence of the L/ST mutant viruses by intracranial inoculation of BALB/c mice. The results of two independent experiments are shown in Table 1. Consistent with published data, wild-type strain 17synϩ was more neurovirulent than KOS and the 17synϩ mutant, 1771, was highly attenuated in these tests. L/ST-n38, although somewhat less virulent than KOS in experiment 1 and somewhat more virulent than KOS in experiment 2, is clearly a neurovirulent virus, demonstrating that the mutation of ORF-P in ORF-P ORF-34.5 double mutants is not responsible for the attenuated phenotypes of these viruses.
The reduced levels of ␥ 1 34.5 transcripts (Fig. 6B ) and the premature shutoff of protein synthesis in SK-N-SH cells observed in in vitro tests of L/ST-4BS (Fig. 8B) predict that L/ ST-4BS might behave in vivo like ORF-P ORF-34.5 doublemutant viruses. As predicted, L/ST-4BS was completely attenuated in both experiments (Table 1) , causing no detect- able morbidity or mortality in mice. Rescue of the mutation in L/ST-4BS restored the wild-type neurovirulence phenotype, confirming that the attenuated phenotype is due to the 4BS mutation.
L/ST-4BS replicates in the mouse eye and in TGG during acute infection following corneal inoculation. Because the attenuation of L/ST-4BS in mice could, in theory, be due to a general defect in the ability of this virus to replicate in mice, we examined the ability of KOS, L/ST-4BS, and L/ST-4BSR to replicate in the mouse eye and in TGG following corneal inoculation. Tear film from four mice and TGG from two mice were collected daily during acute infection (the first 7 days p.i.) and assayed for infectious virus by a standard plaque assay on Vero cell monolayers. The arithmetic mean titers of multiple samples at each time point are shown in Fig. 9 . In tear film, KOS and L/ST-4BSR reached peak titers of approximately 10 5 PFU/ml on day 1 p.i., and these titers were maintained at high levels through day 6 p.i., dropping slightly on day 7 p.i. (Fig.  9A) . Replication of these viruses in TGG was evident by day 2 and peaked between days 3 and 4 p.i. (Fig. 9B) . In both tear film and TGG, L/ST-4BS replicated to near-wild-type levels during the first few days p.i. but exhibited an earlier and more rapid decline in titer thereafter. Rescue of the mutation in L/ST-4BS restored wild-type levels of replication in TGG as in eyes. Notably, these results demonstrate that L/ST-4BS is capable of significant replication (albeit less efficiently than the wild type) in the peripheral nervous system. L/ST-4BS exhibits delayed reactivation from latency in the mouse ocular model. Because the L/STs and/or OPP may be involved in some way in the establishment or reactivation of latency, we examined the ability of the L/ST mutant viruses to reactivate from latently infected mouse TGG. In two independent experiments, mice were inoculated with 2 ϫ 10 6 PFU/eye. On day 30 p.i., TGG were removed and cocultivated with Vero cells. The cocultivation medium was then assayed daily for the presence of infectious, reactivated virus. The cumulative percentage of cocultivated ganglia which scored positive for infectious virus in both experiments is shown in Fig. 9 . Consistent with its wild-type phenotype in vitro, L/ST-n38 reactivated with wild-type kinetics and efficiency in both experiments. L/ST-4BS also reactivated but with delayed kinetics and reduced efficiency relative to wild-type virus in both experiments. In experiment 1, reactivation of L/ST-4BS was delayed somewhat and was less efficient than that of the wild type (71% TGG [17 of 24] ) by day 15 postexplant versus 100% of TGG [24 of 24] by day 6). In this experiment, it was not determined whether the TGG remaining on day 15 harbored latent L/ST-4BS virus; therefore, in the second experiment, explant cocultures were monitored for an extended period (21 days postexplant). In 
DISCUSSION
The abbЈcЈaЈca repeats of the HSV-1 genome contain genes and cis-acting elements that play central roles in establishing the programs of gene expression characteristic of productive infection and latency. The large number of these genes and elements and the extent to which they overlap have complicated the genetic and functional analysis of this region of the genome in that mutations introduced into one gene or element invariably alter the nucleotide sequence of other overlapping genes and elements. Such has been the case in studies of the ␥ 1 34.5 gene, which is encoded on the DNA strand opposite that specifying the L/STs and OPP (Fig. 10) . For these reasons, we endeavored to design mutations that have minimal effects on ORF-34.5 in an effort to elucidate the function(s) of the L/STs and OPP.
OPP does not play a major role in neurovirulence or latency in murine models. To examine the contributions of mutations in ORF-P to the in vitro premature protein shutoff and in vivo neurovirulence and latency phenotypes of ORF-34.5 ORF-P double mutants, we constructed mutant virus L/ST-n38, containing a single-base-pair single-frame nonsense mutation at codon 38 in ORF-P. Before the n38 mutation was introduced into the viral genome, the phenotype of a plasmid carrying this mutation was established in vitro. In transient-expression assays, the n38 mutation terminated the translation of ORF-P prematurely but had no effect on the transcription of the L/STs (Fig. 3) . In the context of viral infection, the n38 mutation (i) had no detectable effect on virus replication in neural (SK-N-SH) or nonneural (Vero) cells (Fig. 5) ; (ii) had no effect on the levels of the L/STs, ␥ 1 34.5, ICP0, or ICP4 transcripts or the LATs in neural (NB41A3) or nonneural (Vero) cells (Fig. 6) ; and (iii) did not produce premature shutoff of infected SK-N-SH cell protein synthesis (Fig. 8) . Consistent with the absence of a unique phenotype in in vitro tests, L/ST-n38 was wild type with regard to neurovirulence, latency, and reactivation in mice. Although the n38 mutation in ORF-P is a singlebase-pair, single-frame nonsense mutation, the G-to-A nucleotide transition also induced an Arg-to-Thr change at amino acid 93 of ORF-O (Fig. 10) . If OOP is involved in any of the functions measured by our in vitro or in vivo assays, the Argto-Thr substitution in L/ST-n38 had no detectable effect on these functions.
What, then, is the function of OPP? Using a yeast two-hybrid system, Bruni and Roizman have presented evidence that OPP interacts with the p32 component of the splicing factor, SF2/ASF (8) . If this interaction proves to be specific, its functional consequences for HSV replication remain to be determined. Based on studies of ORF-P ORF-34.5 double mutants, these investigators have implicated OPP in blocking the synthesis of the spliced transcripts of the ICP0 and 22 genes early (8 h) but not late (18 h) in infection. As noted above (Fig. 6) , we detected no difference in the levels of ICP0 transcripts (or proteins [data not shown]) at early times (6 h) p.i. in L/STn38-infected Vero and NB41A3 cells relative to wild-type virus-infected cells. Thus, at this writing, no phenotype has been demonstrated for L/ST-n38 and the function of OPP remains unknown. Although it does not appear to be a major player in neurovirulence or in latency and reactivation in mice, our results do not preclude the possibility that OPP functions during productive or latent infections in humans.
L/ST-4BS exhibits in vitro and in vivo properties characteristic of ORF-P ORF-34.5 double mutants. The second mutation used to examine the function of ORF-P ORF-34.5 double mutants, 4BS, alters the ICP4 binding site 4 bp upstream of the transcriptional start site of the L/STs. As anticipated, tests conducted before the transfer of this mutation into the viral genome demonstrated that the 4BS mutation abrogates the binding of ICP4 to its cognate repressive binding site (Fig. 4A) . Notably, this mutation had no effect on the ability of ICP4 or ICP0 to activate the expression of a reporter gene from the same mutant promoter in cotransfection and transfection/superinfection assays, demonstrating that the sequences responsible for ICP0-ICP4-mediated activation of the L/ST promoter do not include the repressive ICP4 binding site (Fig. 4B to D) .
The in vitro and in vivo phenotypic properties of L/ST-4BS are summarized in Table 2 . Several points can be made from these findings. tested, implicating neural factors specifically in the low-level expression of these two immediate-early genes.
Second, the 4BS mutation, which resulted in the (expected) high-level expression of the L/STs, was (unexpectedly) accompanied by the nearly complete absence of ␥ 1 34.5 transcripts and the LATs in neural (NB41A3, SK-N-SH, and PC12) but not nonneural (Vero) cells. We conclude, therefore, that expression of these two families of transcripts is regulated differentially in the two cell types (Fig. 6B and D) and that the genomic locus in which the 4BS mutation in L/ST-4BS lies controls the expression of both the ␥ 1 34.5 transcripts and the LATs in neural cells.
What is the molecular basis of the nearly total absence of ␥ 1 34.5 transcripts and the LATs in L/ST-4BS-infected neural cells? Based on the location of the 4BS mutation (Fig. 10) , several possibilities present themselves. First, because the 4BS mutation lies in the ICP4 binding site in the L/ST promoter, overexpression of the L/STs and the multiple proteins which they potentially encode may downregulate ␥ 1 34.5 and LAT expression. Clearly, however, the putative L/ST-encoded downregulatory protein(s) is not OPP, since the levels of ␥ 1 34.5 transcripts and the LATs were nearly wild type in L/ST-n38-infected NB41A3 cells, which produce a severely truncated and probably nonfunctional form of OPP. Second, the 4BS mutation in ORF-O sequences may produce this result. As noted above and as shown in Fig. 10 , the 4BS mutation lies in sequences encoding OOP. (Although Randall et al. [34] have recently presented evidence suggesting that translation of ORF-O actually begins at the ORF-P translational start site in HSV-1 strain F, no evidence to support this contention has yet been obtained for strain KOS or other HSV-1 strains.) If OOP is encoded by the LATs, as suggested above, and if OOP activates the expression of both ␥ 1 34.5 and the LATs by a positivefeedback mechanism, the 4BS mutation in ORF-O would result in the failure of OPP to activate ␥ 1 34.5 transcription and LAT expression. Third, the 4BS mutation may lie in an unrecognized gene or element that controls the expression of ␥ 1 34.5 and LAT transcription.
Notably, the reduced levels of ␥ 1 34.5 transcripts and the LATs in L/ST-4BS-infected NB41A3 cells are not likely to be due to the instability of these transcripts as a consequence of the 4BS mutation (which alters the nucleotide sequence of both classes of transcript), because these mutated transcripts were as stable as their wild-type counterparts in L/ST-4BS-infected Vero cells. Similarly, the reduced levels of ␥ 1 34.5 transcripts and the LATs in L/ST-4BS-infected neural cells is not likely to be due to antisense repression by the L/STs (as has been suggested recently [35] ), because wild-type levels of these transcripts, which lie ϳ0.5 kb upstream of the 4BS mutation, were produced in L/ST-4BS-infected Vero cells, which also expressed high levels of the L/STs (Fig. 6) .
Whatever the mechanism underlying their repression, the absence of ␥ 1 34.5 transcripts in L/ST-4BS-infected NB41A3 cells is consistent with the premature shutoff of infected-cell protein synthesis in neural cells and the neuroattenuation characteristic of ORF-P ORF-34.5 double mutants. In addition, the absence of the LATs in L/ST-4BS-infected neural cells is consistent with the delay in and reduced efficiency of reactivation, which is characteristic of LAT-minus viruses (27) .
The results of our characterization of L/ST-4BS are in general agreement with the published properties of another virus mutated in the ICP4 binding site in the L/ST promoter, R7530 (also called ORFP ϩϩ [25] ). The most significant difference between the two viruses is that R7530 induced no detectable ␥ 1 34.5 transcripts yet premature shutoff of protein synthesis in SK-N-SH cells was not observed, whereas L/ST-4BS exhibited greatly reduced levels of ␥ 1 34.5 transcripts as well as premature shutoff of host protein synthesis. It may be that the two properties (synthesis of ␥ 1 34.5 transcripts and premature protein shutoff, which are thought to represent cause and effect, respectively) are regulated differentially. Whatever the answer to this puzzling question, it is likely that the differences in the phenotypes of the two mutant viruses reflect differences in the specific mutations introduced into the ICP4 binding sites of strains F and KOS (25) , as well as differences in the properties of the wild-type strains from which the two mutants were derived.
We conclude from our studies of L/ST-n38 and L/ST-4BS that (i) mutations in ORF-34.5 and not in ORF-P are responsible for the attenuated phenotype of ORF-34.5 ORF-P double mutants, (ii) the function of OPP remains unknown, (iii) expression of the ␥ 1 34.5 gene and the LATs in cells of neural lineage is regulated directly or indirectly by elements in the locus marked by the 4BS mutation, (iv) expression of the ␥ 1 34.5 transcripts and the LATs is regulated similarly in cells of neural lineage, and (v) ␥ 1 34.5 and LAT transcription is regulated differently in cells of neural and nonneural lineage. 
